
Annual report 2024
added 12-13-2025
Check-Cap Ltd. Retained Earnings 2011-2025 | CHEK
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings Check-Cap Ltd.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -170 M | -145 M | -127 M | -108 M | -91 M | -77.1 M | -63.3 M | -52.7 M | -42.9 M | -34.1 M | -26.6 M | -22.5 M | -18.5 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -18.5 M | -170 M | -75.3 M |
Quarterly Retained Earnings Check-Cap Ltd.
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | -108 M | - | -98.5 M | - | -91 M | - | -83.5 M | - | -77.1 M | - | -69.8 M | - | -63.3 M | - | -57.5 M | - | -52.7 M | - | -48.4 M | - | -42.9 M | - | -38.8 M | - | -34.1 M | - | - | - | -21.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -21.8 M | -108 M | -63.4 M |
Retained Earnings of other stocks in the Diagnostics research industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
-62.9 M | - | -6.23 % | $ 30.6 M | ||
|
Akumin
AKU
|
-280 M | - | -17.87 % | $ 25.9 M | ||
|
Brainsway Ltd.
BWAY
|
-77.3 M | $ 16.75 | -1.28 % | $ 99.4 M | ||
|
Burning Rock Biotech Limited
BNR
|
-2.23 B | $ 16.9 | 7.3 % | $ 183 M | ||
|
Accelerate Diagnostics
AXDX
|
-607 M | - | -61.36 % | $ 2.46 M | ||
|
Biocept
BIOC
|
-298 M | - | -13.05 % | $ 7.29 M | ||
|
BioNano Genomics
BNGO
|
-693 M | $ 1.57 | -3.08 % | $ 2 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
-84 M | - | - | $ 562 M | ||
|
Castle Biosciences
CSTL
|
-200 M | $ 38.44 | -0.5 % | $ 1.07 B | ||
|
DarioHealth Corp.
DRIO
|
-349 M | $ 12.0 | 0.93 % | $ 340 M | ||
|
Chembio Diagnostics
CEMI
|
-154 M | - | 0.22 % | $ 16.8 M | ||
|
DexCom
DXCM
|
1.02 B | $ 66.39 | -0.85 % | $ 25.6 B | ||
|
Danaher Corporation
DHR
|
44.2 B | $ 226.5 | - | $ 166 B | ||
|
Exact Sciences Corporation
EXAS
|
-4.5 B | $ 101.57 | 0.07 % | $ 18.8 B | ||
|
Fulgent Genetics
FLGT
|
590 M | $ 26.81 | -1.22 % | $ 811 M | ||
|
Global Cord Blood Corporation
CO
|
2.89 B | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
-624 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
-150 M | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
-4.94 B | - | 0.12 % | $ 80.1 M | ||
|
DermTech
DMTK
|
-424 M | - | -11.32 % | $ 2.94 M | ||
|
PRA Health Sciences, Inc.
PRAH
|
440 M | - | - | $ 10.7 B | ||
|
CareDx, Inc
CDNA
|
-678 M | $ 19.74 | -3.99 % | $ 1.06 B | ||
|
Celcuity
CELC
|
-272 M | $ 102.0 | -3.09 % | $ 4.02 B | ||
|
Enzo Biochem
ENZ
|
-294 M | - | -8.98 % | $ 14.8 K | ||
|
Anixa Biosciences
ANIX
|
-241 M | $ 3.53 | -1.4 % | $ 113 K | ||
|
Co-Diagnostics
CODX
|
4.6 M | $ 0.31 | -9.4 % | $ 9.1 M | ||
|
Quidel Corporation
QDEL
|
945 M | $ 28.81 | 0.03 % | $ 1.21 B | ||
|
IQVIA Holdings
IQV
|
6.06 B | $ 222.3 | 0.04 % | $ 40.3 B | ||
|
Guardant Health
GH
|
-2.58 B | $ 103.47 | 1.37 % | $ 12.7 B | ||
|
Aspira Women's Health
AWH
|
-499 M | - | -6.19 % | $ 10.5 M | ||
|
Heska Corporation
HSKA
|
-169 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
-230 M | - | -20.0 % | $ 1.06 M | ||
|
Illumina
ILMN
|
-1.24 B | $ 133.88 | -0.73 % | $ 21.3 B | ||
|
Charles River Laboratories International
CRL
|
1.81 B | $ 196.14 | 1.64 % | $ 10.1 B | ||
|
Quotient Limited
QTNT
|
-600 M | - | -11.32 % | $ 1.1 M | ||
|
Quest Diagnostics Incorporated
DGX
|
9.36 B | $ 183.36 | 0.47 % | $ 20.4 B | ||
|
Biodesix
BDSX
|
-462 M | $ 7.56 | -3.63 % | $ 980 M | ||
|
Mettler-Toledo International
MTD
|
8.37 B | $ 1 410.24 | 1.17 % | $ 29.9 B | ||
|
Laboratory Corporation of America Holdings
LH
|
8.3 B | $ 262.29 | -0.71 % | $ 22 B | ||
|
Myriad Genetics
MYGN
|
-757 M | $ 7.01 | -2.84 % | $ 635 M | ||
|
ICON Public Limited Company
ICLR
|
2.72 B | $ 183.39 | -1.71 % | $ 15.1 B | ||
|
IDEXX Laboratories
IDXX
|
5.33 B | $ 701.16 | -0.43 % | $ 57.8 B | ||
|
Lantheus Holdings
LNTH
|
446 M | $ 67.34 | 1.08 % | $ 4.66 B | ||
|
NeoGenomics
NEO
|
-326 M | $ 12.07 | 1.81 % | $ 1.53 B | ||
|
Neogen Corporation
NEOG
|
-536 M | $ 6.8 | -0.95 % | $ 1.47 B | ||
|
Agilent Technologies
A
|
348 M | $ 140.63 | 0.69 % | $ 42.8 B | ||
|
Biomerica
BMRA
|
-53.2 M | $ 2.56 | 0.29 % | $ 5.88 M | ||
|
Bioventus
BVS
|
-322 M | $ 7.59 | 0.53 % | $ 475 M | ||
|
Motus GI Holdings
MOTS
|
-154 M | - | -34.28 % | $ 263 K |